Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2008.115378v1, 2008; 10.1373/clinchem.2008.115378
This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2008.115378v1
55/1/139    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meyer, K.
Right arrow Articles by Ueland, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meyer, K.
Right arrow Articles by Ueland, P. M.

Received on July 30, 2008
Accepted on October 23, 2008

Automation and Analytical Techniques

MALDI-TOF MS Genotyping of Polymorphisms Related to 1-Carbon Metabolism Using Common and Mass-Modified Terminators

Klaus Meyer 1*, Åse Fredriksen 2, Per Magne Ueland 3

1 Bevital A/S, Armauer Hansens Hus, Bergen, Norway, and Section for Pharmacology, Institute of Medicine, Armauer Hansens Hus, University of Bergen, Bergen, Norway
2 Section for Pharmacology, Institute of Medicine, Armauer Hansens Hus, University of Bergen, Bergen, Norway
3 Section for Pharmacology, Institute of Medicine, Armauer Hansens Hus, University of Bergen, Bergen, Norway, and Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway

* To whom correspondence should be addressed. E-mail: klaus.meyer{at}farm.uib.no.

BACKGROUND: Large cohort studies may provide sufficient power to disentangle the role of polymorphisms related to 1-carbon metabolism and chronic diseases, but they require fast, accurate, high-throughput genotyping techniques. MALDI-TOF mass spectrometry has been adapted to rapid fine mapping using various approaches for allele discrimination. We developed a genotyping method based on MALDI-TOF MS and compared assay performance for formats based on standard and mass-modified terminators.

METHODS: The assay includes 20 polymorphisms of 14 genes involved in 1-carbon metabolism (BHMT 742G>A, CBS 844ins68 and 699C>T, CTH 1364G>T, DHFR del19, NOS3 –786T>C and 894G>T, FOLR1 1314A>G, MTHFD1 –105T>C and 1958G>A, MTHFR 677C>T and 1298A>C, MTR 2756A>G, MTRR 66A>G and 524C>T, SLC19A1 80G>A, SHMT2 1420C>T, TCN2 67A>G and 776C>G, and TYMS 1494del6).

RESULTS: Missing calls were observed for 4.7% of the DNA samples, attributed to failed liquid sample handling. Highly accurate genotyping was obtained by mass-modified as well as standard ddNTPs, with an average error rate of ≤0.1% by analysis of sample duplicates. A semiquantitative approach enabled unambiguous identification of the CBS 844ins68. Cluster plots of the relative allele intensities showed allele-specific bias according to type of minisequencing terminator and revealed a potential structural variation in the BHMT gene.

CONCLUSIONS: MALDI-TOF MS–based genotyping using either standard or mass-modified terminators allows the accurate determination of single nucleotides as well as structural genetic variants. This was demonstrated with 20 polymorphisms involved in 1-carbon metabolism.




The following articles in journals at HighWire Press have cited this article:


Home page
JAMAHome page
M. Ebbing, K. H. Bonaa, O. Nygard, E. Arnesen, P. M. Ueland, J. E. Nordrehaug, K. Rasmussen, I. Njolstad, H. Refsum, D. W. Nilsen, et al.
Cancer Incidence and Mortality After Treatment With Folic Acid and Vitamin B12
JAMA, November 18, 2009; 302(19): 2119 - 2126.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the American Association for Clinical Chemistry.